Brukinsa Approved for Waldenström Macroglobulinemia
The approval was based on data from the phase 3 ASPEN trial.
Hematologic Cancers
Dosing Schedule of Intravenous Bisphosphonate Has Little Effect on Recurrent Skeletal-Related Events in Patients With Multiple Myeloma
No significant difference in SRE risk on the basis of intravenous bisphosphonate dosing was observed for patients with newly diagnosed multiple myeloma.
MPR Weekly Dose Podcast 84
The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. Revisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Meanwhile,…
Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia
Eight patients had a complete response within 1 month of infusion.
Model May Identify Non-ETP T-ALL Patients at High Risk of Poor Response to Treatment
The model appears to predict minimal residual disease status.
Response-Based Ponatinib Dosing Appears Effective in Chronic Phase Chronic Myeloid Leukemia
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
High CMR Rates With Ponatinib Plus Blinatumomab in Adult Ph+ ALL
Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.
Additional Tablet Strengths of Xpovio Now Available
The additional strengths are intended to increase patient compliance and reduce pill burden.
First CAR T-Cell Therapy Approved for Indolent Follicular Lymphoma
The approval was based on data from the single-arm, open-label phase 2 ZUMA-5 study.
FDA Accepts sNDA for Brukinsa in Waldenström Macroglobulinemia
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
